查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837182

血管損傷治療市場按產品、治療方式、最終用戶和損傷類型分類－2025-2032年全球預測

Vascular Injury Treatment Market by Product, Treatment Modalities, End User, Injury Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血管損傷治療市場規模將達到 705.2 億美元，複合年成長率為 14.15%。

關鍵市場統計數據
基準年 2024 244.5億美元
預計年份：2025年 279.2億美元
預測年份 2032 705.2億美元
複合年成長率 (%) 14.15%

將不斷變化的臨床、營運和商業性需求置於更廣闊的背景下進行分析，這些需求正在重塑血管損傷治療路徑和相關人員的優先事項。

血管損傷治療處於急性期護理、擇期手術和長期血管健康管理的關鍵交會點。近年來，器械小型化、影像引導手術和標靶藥物治療的進步正在再形成臨床路徑，並促使醫療服務提供者和支付者重新評估治療方案和籌資策略。同時，人口結構的變化和損傷模式的演變要求治療系統能夠適應變化，及時止血、恢復灌注並減少後續併發症。

本章概述了該領域創新所面臨的關鍵臨床挑戰和相關人員。臨床醫師越來越重視能夠縮短手術時間和降低併發症風險的工具，而醫院管理者則越來越重視單次治療成本和吞吐量。投資者和製造商傾向於採用模組化平台和可互通的組件，以適應多種治療方式。這些壓力匯聚在一起，使得臨床療效必須與營運可行性相平衡，而監管政策的清晰度和報銷途徑將決定哪些技術能夠規模化應用。

展望未來，策略規劃不僅要考慮設備性能和藥物療效，還要考慮實施因素，例如培訓、供應鏈韌性以及與數位化診斷工作流程的整合。透過將臨床效用與系統層面的經濟效益結合，相關人員可以在改善患者預後的同時，維持永續的營運模式。

器械創新、診斷影像技術的進步以及基於價值的採購如何融合，重新定義了血管損傷治療領域的治療選擇和競爭動態。

過去五年，由於器械工程、藥物治療和手術全期影像技術的進步，血管損傷的治療格局發生了顯著變化。微創血管內治療方法已從小眾治療方法發展成為許多動脈和靜脈損傷的第一線治療方法，從而改變了轉診模式和醫院服務結構。同時，顯像模式和術中導航系統的改進提高了病灶定位的準確性，降低了手術誤差，從而擴大了介入治療的適用人群。

除了臨床工具之外，監管要求和以價值為導向的採購模式也獎勵製造商展現明確的療效和工作流程效率。這加速了將支架設計與輸送導管和輔助藥物療法相結合的整合解決方案的開發。同時，器械開發人員優先考慮材料科學領域的創新，開發出具有更高生物相容性和耐久性的塗層支架和藥物釋放型支架。因此，器械和藥物之間的競爭界線日益模糊，促使跨學科合作的發展。

這種轉變對市場動態有重要影響。能夠提供以真實世界證據和培訓項目為支撐的端到端解決方案的供應商，更有可能贏得長期合約。實際上，該行業正朝著一個將臨床路徑貫穿急診和擇期護理的生態系統發展，從而為整合式護理模式和打包支付試點計畫創造機會。

評估 2025 年關稅調整如何促使血管器械和藥品供應商進行供應鏈重組、區域製造轉移和策略成本管理。

2025年的貿易政策調整和關稅重新分類給醫療設備和某些醫藥原料的全球供應鏈帶來了明顯的摩擦。依賴跨境採購的製造商面臨更高的到岸成本和更複雜的採購計畫。這些成本壓力促使製造商採取了多項策略性應對措施，包括供應鏈區域化、重新談判供應商條款以及加快替代供應商的資格認證，以維持生產的連續性。

不同產品類型所受到的累積影響各不相同。高度複雜的植入和精準輸送系統對關稅導致的成本波動更為敏感，因為它們的製造地通常跨越多個司法管轄區。相較之下，通用一次性拋棄式和本地生產的藥物製劑受到的影響較小。因此，一些製造商將生產和組裝轉移到更靠近終端市場的地方，以減輕未來貿易波動的影響，而另一些製造商則承擔了短期成本以維持現有的分銷關係。

臨床醫生和醫院採購團隊的回應是，他們更加關注醫療保健總成本，而不僅僅是單位成本，這推動了對能夠顯著縮短住院時間、降低再次手術率和手術時間的產品的需求。對於製造商和供應鏈領導者而言，2025年的關稅情況凸顯了靈活性的戰略價值，例如供應商多元化、投資本地製造能力以及建立合約機制以在貿易夥伴之間共用風險。

透過深度細分洞察，調整產品系列、手術流程、護理環境和損傷類型，以最佳化臨床適用性和商業性吸引力。

細分市場提供了一種結構化的方法，透過將臨床需求和購買行為與產品、治療方式、最終用戶和損傷類型聯繫起來，從而優先考慮開發和商業策略。在產品類型中，導管分為抽吸導管、球囊導管和輸送導管，每種導管都扮演不同的角色。支架的選擇範圍很廣，從裸金屬支架到塗層支架和藥物釋放型支架，可應對不同的血管病變和癒合情況。藥物介入措施包括溶栓劑，例如鏈球菌激酶、組織纖維蛋白溶酶原活化劑和尿激酶，它們的給藥方案和風險特徵各不相同。

治療方式的細分突顯了臨床路徑，這些路徑會改變採購和訓練需求。血管內修復涵蓋主動脈、頸動脈和周邊置入術置入術，這些都需要特定的輸送系統和影像支援；而對於複雜的重組或不適合微創技術的病例，開放性手術仍然至關重要。藥物治療分為抗凝血劑、抗血小板藥物和溶栓劑，體現了它們與器械介入治療的互補性，並為圍手術期通訊協定的製定提供了依據。

終端使用者細分區分了門診手術中心、醫院和專科診所，它們各自的資本投資能力、病例組合和人員配備水準各不相同。此外，損傷類型細分（包括動脈損傷、毛細血管損傷、微血管損傷和靜脈損傷）指南臨床優先排序和產品選擇，因為器械和藥物的療效會因血管口徑和血流動力學的不同而有所差異。整合這種細分視角，能夠幫助相關人員將臨床價值提案和商業化策略與買方需求和醫療服務實際情況相協調。

美洲、歐洲、中東和非洲以及亞太地區的招募模式、監管預期和供應鏈策略

區域動態影響技術採納時間表、報銷框架和監管預期，進而影響投資重點。在美洲，研發中心和綜合醫療系統正在推動先進血管內治療平台的快速普及，而採購方則越來越關注療效記錄和打包式醫療服務模式。在歐洲、中東和非洲，各國報銷體系的差異導致了技術採納率的差異。一些市場強調成本控制和集中採購，而另一些市場則優先考慮在三級醫療中心獲得最先進治療。在亞太地區，人口成長和醫院基礎設施的擴建推動了對設備升級和手術能力提升的持續需求，但區域製造和監管方面的細微差別正在影響供應商的參與策略。

各地區在安全性和上市後監測方面的監管趨同正在提高臨床證據的標準，而對數位化互通性的期望正成為能夠實現結果追蹤的供應商的差異化優勢。此外，區域供應鏈的韌性已成為一項策略重點，推動了對區域分銷中心和區域組裝能力的投資。對於商業領導者而言，成功需要根據區域臨床重點和採購框架調整價值訊息和證據材料，同時保持可擴展的全球營運模式，以適應當地監管和經濟波動。

技術創新、策略夥伴關係和服務產品如何改變醫療設備和治療服務提供者的競爭優勢和商業化策略

血管損傷治療領域的競爭動態日益激烈，那些將技術創新與可靠的臨床證據和可擴展的商業模式相結合的贊助商將獲得豐厚的回報。市場領導正致力於投資差異化的器械平台、平台擴充性以及培訓和指導等手術支援服務。器械製造商與製藥公司之間的夥伴關係應運而生，旨在打造捆綁式解決方案，簡化臨床決策並促進整合式治療路徑的建構。規模較小、更靈活的公司持續推動導管設計、支架塗層和輔助性治療的顛覆性創新，吸引尋求拓展產品組合的大型公司進行策略性投資和簽署許可協議。

智慧財產權管理、監管執法速度以及嚴謹的臨床試驗設計方法將決定哪些公司能夠獲得新適應症的研發資金。同樣重要的是分銷網路和醫院關係，它們能夠幫助公司在核准後迅速擴大規模。模擬訓練、療效監測和報銷支援等服務要素已成為影響採購決策的關鍵差異化因素。對現有企業而言，持續創新和卓越營運是捍衛市場地位的必要條件；而新參與企業則必須展現出清晰的臨床效益和路徑整合能力，才能突破根深蒂固的採購流程。

為製造商和醫療系統領導者提供可操作的策略重點，以確保臨床應用、加強供應鏈和協調報銷途徑。

產業領導者應採取三管齊下的策略，平衡產品組合最佳化、營運韌性和相關人員參與。首先，優先投資於模組化平台和輔助服務，這些平台和服務能夠顯著縮短手術時間、減少併發症並降低後續資源利用率。此類解決方案應以可操作的臨床研究為支撐，並專注於能夠引起臨床醫生和採購團隊共鳴的真實世界結果。其次，透過供應商多元化、尋找區域性生產方案以及與貿易夥伴協商靈活的合約共用成本波動，來降低供應鏈風險。這將有助於在政策和物流中斷期間快速恢復供應，同時保持利潤率。

第三，將商業化與教育和實證實踐結合。開發可擴展的培訓項目和數位化工具，以促進臨床醫生採納並收集上市後績效數據。同時，與支付者和醫院價值委員會進行有針對性的舉措，以協調報銷和採購獎勵。最後，探索策略夥伴關係和授權協議，以加速利基創新產品的市場准入並節省資金。透過同時實現產品差異化、強化供應鏈和協調相關人員，產業領導者可以將創新轉化為永續的市場准入和臨床影響。

一套透明的調查方法框架，結合了對臨床醫生和採購負責人的初步訪談、嚴謹的二手證據綜合分析以及基於情境的檢驗。

本研究整合了主要相關人員訪談、二手文獻研究以及臨床和商業資料的交叉檢驗，以確保方法的嚴謹性和透明度。主要資訊來源包括與介入臨床醫生、醫院採購負責人和供應鏈高管進行的結構化討論，以了解實際限制、推廣障礙和臨床偏好。二手研究包括同行評審的臨床研究、監管文件和公開採購文件，以檢驗設備和治療方法的特性並驗證已報告的趨勢。

此分析方法結合了質性主題分析和定量交叉表列，以探討採納促進因素與結果之間的相關性。研究採用證據等級體系，對隨機臨床試驗數據、註冊研究數據和真實世界數據進行權衡，確保得出與政策相關的結論。此外，還進行了敏感性分析和情境測試，以評估研究結果在報銷和供應鏈狀況可能出現的變化下的穩健性。研究始終強調數據的可追溯性和邏輯的可複現性，確保研究結果能為戰術性商業性決策和長期研發優先事項提供基礎。

策略意義的整合以及臨床證據、營運執行和供應鏈敏捷性之間的關鍵相互作用將塑造未來的成功。

血管損傷治療領域正處於曲折點，技術成熟、政策轉變和不斷演進的醫療服務模式既帶來了機遇，也帶來了挑戰。能夠將產品功能與臨床和營運效益相結合的器材和藥物創新者，將能夠獲得優先採購管道。貿易和供應格局的變化將提升生產彈性和合約創新的策略重要性，而監管和報銷方面的區域差異則要求企業採取在地化的市場准入策略。

最終的成功取決於將產品創新與教育、實證實踐和供應鏈韌性相結合。投資於以結果為導向的價值提案和可擴展實施支持的相關人員將更有能力影響醫療路徑並獲得長期價值。未來的道路將有利於那些能夠將卓越的臨床水平與切實可行的系統級解決方案相結合，從而在改善患者預後的同時實現永續商業性回報的合作者。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大藥物釋放型球囊在複雜性周邊血管損傷治療的應用
  • 血管內機器人輔助系統的普及提高了創傷治療的精準度
  • 開發含有奈米顆粒的多功能止血敷料，用於快速控制出血
  • 運用人工智慧驅動的預測分析最佳化血管創傷患者的診療路徑
  • 用於動脈損傷修復的微創經皮機械血栓除去裝置的發展
  • 加強生物技術公司與學術機構在再生血管治療領域的合作
  • 3D列印、可客製化血管移植物因其能更好地適應複雜損傷而興起
  • 著重研究血流動力學監測技術，以改善血管創傷的治療效果

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血管損傷治療市場：依產品分類

  • 導管
    • 吸管
    • 球囊導管
    • 輸送導管
  • 栓塞保護裝置
    • 遠端濾器
    • 近端閉塞裝置
  • 支架
    • 裸金屬支架
    • 覆膜支架
    • 藥物釋放型支架
  • 溶栓藥物
    • 鏈球菌激酶
    • 組織型胞漿素原原活化劑
    • 尿激酶
  • 血管移植
    • 生物移植
    • 合成接枝

第9章 血管損傷治療市場：依治療方式分類

  • 血管內修復
    • 主動脈支架置入術
    • 頸動脈置入術
    • 外周支架置入術
  • 開放性手術
  • 藥物治療
    • 抗凝血劑
    • 抗血小板藥物
    • 溶栓藥物

第10章 血管損傷治療市場（依最終使用者分類）

  • 門診手術中心
  • 醫院
  • 專科診所

第11章 按損傷類型分類的血管損傷治療市場

  • 動脈損傷
  • 毛細血管損傷
  • 微血管損傷
  • 靜脈損傷

第12章 血管損傷治療市場：按地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 血管損傷治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國血管損傷治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Medtronic plc
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Johnson & Johnson
    • WL Gore & Associates, Inc.
    • Terumo Corporation
    • B. Braun Melsungen AG
    • Becton, Dickinson and Company
    • Teleflex Incorporated
    • Edwards Lifesciences Corporation
Product Code: MRR-034B5003037C

The Vascular Injury Treatment Market is projected to grow by USD 70.52 billion at a CAGR of 14.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 24.45 billion
Estimated Year [2025] USD 27.92 billion
Forecast Year [2032] USD 70.52 billion
CAGR (%) 14.15%

Contextualizing the evolving clinical, operational, and commercial imperatives that are reshaping vascular injury treatment pathways and stakeholder priorities

Vascular injury treatment occupies a critical intersection of acute care, elective intervention, and long-term vascular health management. Recent advancements in device miniaturization, imaging-guided procedures, and targeted pharmacotherapies have reshaped clinical pathways, prompting providers and payers to re-evaluate protocols and procurement strategies. At the same time, demographic shifts and evolving trauma patterns require adaptable systems of care that can deliver timely hemostasis, restore perfusion, and limit downstream complications.

This section frames the major clinical imperatives and stakeholder priorities that underpin innovation in the field. Clinicians increasingly prioritize tools that reduce procedure time and complication risks, while hospital administrators focus on cost per episode and throughput. Investors and manufacturers are tilting toward modular platforms and cross-compatible components that can support multiple treatment modalities. These converging pressures have created a landscape where clinical efficacy must be balanced with operational viability, and where regulatory clarity and reimbursement pathways determine which technologies achieve scale.

Moving forward, strategic planning must incorporate not only device performance and drug efficacy, but also implementation factors such as training, supply chain resilience, and integration with digital diagnostic workflows. By aligning clinical utility with system-level economics, stakeholders can improve patient outcomes while maintaining sustainable operational models.

How device innovation, imaging advances, and value-based procurement have converged to redefine treatment options and competitive dynamics in vascular injury care

The past five years have seen transformative shifts in the vascular injury landscape driven by convergent advances in device engineering, pharmacotherapy refinement, and perioperative imaging. Minimally invasive endovascular techniques have matured from niche applications into frontline options for many arterial and venous injuries, altering referral patterns and hospital service mix. Simultaneously, enhanced imaging modalities and intra-procedural guidance systems have improved lesion targeting and reduced the margin for error, thereby expanding the candidate pool for intervention.

Beyond clinical tools, regulatory adaptations and value-centric procurement models have incentivized manufacturers to demonstrate clear outcomes and workflow efficiencies. This has accelerated the development of integrated solutions that combine stent designs with delivery catheters and adjunctive pharmacologic regimens. In parallel, device developers have prioritized materials science innovations, producing covered and drug-eluting stents with improved biocompatibility and durability. As a result, the competitive boundary between devices and drugs has blurred, compelling cross-disciplinary collaboration.

These shifts have important implications for market dynamics: suppliers that can offer end-to-end solutions, supported by real-world evidence and training programs, are better positioned to win long-term contracts. In effect, the field is moving toward ecosystems that lock-in clinical pathways across acute and elective care settings, creating opportunities for integrated care models and bundled payment pilots.

Assessing how 2025 tariff adjustments prompted supply chain realignment, localized manufacturing shifts, and strategic cost management across vascular device and drug suppliers

Trade policy adjustments and tariff reclassifications in 2025 introduced measurable friction into global supply chains for medical devices and certain pharmacologic inputs. Manufacturers reliant on cross-border component sourcing faced increased landed costs and greater complexity in procurement planning. These cost pressures prompted several strategic responses including regionalization of supply chains, renegotiation of supplier terms, and accelerated qualification of alternative suppliers to preserve manufacturing continuity.

The cumulative impact on the vascular injury treatment ecosystem has been uneven across product categories. High-complexity implants and precision delivery systems were particularly sensitive to tariff-induced cost movements because their manufacturing footprints often span multiple jurisdictions. In contrast, commodity disposables and locally produced pharmacologic agents encountered fewer disruptions. Consequently, some manufacturers shifted production or assembly closer to end markets to mitigate future trade volatility, while others absorbed near-term costs to preserve established distribution relationships.

Clinicians and hospital procurement teams responded by increasing scrutiny on total cost of care rather than unit price alone, driving demand for products that demonstrably reduce length of stay, reintervention rates, and procedural time. For manufacturers and supply chain leaders, the 2025 tariff landscape underscored the strategic value of flexibility: diversifying suppliers, investing in localized manufacturing capacity, and building contractual mechanisms to share risk across trading partners.

Deep segmentation-driven insights that align product portfolios, procedural pathways, care settings, and injury types to optimize clinical fit and commercial traction

Segmentation provides a structured way to prioritize development and commercial strategies by linking clinical need with purchasing behavior across products, modalities, end users, and injury types. Within product categories, catheters encompass aspiration, balloon, and delivery variants that each serve distinct procedural roles, while embolic protection devices divide into distal filters and proximal occlusion technologies that reduce downstream embolic load. Stent options range from bare metal designs to covered and drug-eluting technologies that address differing vessel pathologies and healing profiles. Pharmacologic interventions include streptokinase, tissue plasminogen activator, and urokinase as thrombolytic agents with varied dosing paradigms and risk profiles, and vascular grafts are offered in biological and synthetic formats for reconstructive use.

Treatment modality segmentation highlights clinical pathways that alter procurement and training needs. Endovascular repair spans aortic, carotid, and peripheral stenting approaches that require specific delivery systems and imaging support, whereas open surgery remains essential for complex reconstructions and cases unsuitable for minimally invasive techniques. Pharmacotherapy segmentation into anticoagulants, antiplatelet drugs, and thrombolytics reflects therapeutic complementarity with device-based interventions and informs peri-procedural protocols.

End-user segmentation differentiates ambulatory surgical centers, hospitals, and specialty clinics, each exhibiting distinct capital expenditure capabilities, case mix, and staffing competencies. Finally, injury-type segmentation across arterial, capillary, microvascular, and venous injuries guides clinical prioritization and product selection, because device and drug efficacy profiles vary by vessel caliber and flow dynamics. Synthesizing these segmentation lenses enables stakeholders to tailor clinical value propositions and commercialization tactics to match buyer needs and care delivery realities.

Regional adoption patterns, regulatory expectations, and supply chain strategies that dictate how suppliers must tailor offerings across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape adoption timelines, reimbursement frameworks, and regulatory expectations that in turn influence investment priorities. In the Americas, innovation centers and integrated health systems facilitate rapid uptake of advanced endovascular platforms, with purchasers increasingly focused on outcome documentation and bundled care models. In Europe, Middle East & Africa, heterogeneity across national reimbursement regimes creates a mosaic of adoption speeds; some markets emphasize cost containment and central purchasing while others prioritize access to cutting-edge therapies in tertiary centers. In the Asia-Pacific region, demographic growth and expanding hospital infrastructure are driving sustained demand for both device upgrades and surgical capacity expansion, though local manufacturing and regulatory nuances affect supplier entry strategies.

Cross-regionally, regulatory convergence on safety and post-market surveillance is raising the bar for clinical evidence, and digital interoperability expectations are emerging as differentiators for suppliers that enable outcome tracking. Additionally, regional supply chain resilience has become a strategic priority, prompting investments in regional distribution hubs and local assembly capabilities. For commercial leaders, success requires tailoring value messaging and evidence dossiers to local clinical priorities and procurement frameworks while maintaining scalable global operating models that can adapt to regional regulatory and economic variables.

How innovation, strategic partnerships, and service-enabled offerings are reshaping competitive advantage and commercialization strategies across device and therapy providers

Competitive dynamics in vascular injury treatment increasingly reward sponsors that pair technological innovation with robust clinical evidence and scalable commercial models. Market leaders are investing in differentiated device platforms, platform extensibility, and procedural support services such as training and proctoring. Partnerships between device manufacturers and pharmacology firms have emerged to create bundled solutions that simplify clinical decision-making and promote integrated pathways. Smaller, agile firms continue to drive disruptive innovation in catheter design, stent coatings, and adjunctive therapies, attracting strategic investment and licensing deals from larger companies seeking to broaden their portfolios.

Intellectual property management, regulatory execution speed, and a disciplined approach to clinical trial design determine who can capitalize on emerging indications. Equally important are distribution networks and hospital relationships that enable rapid scale-up once clearance is achieved. Service components-such as simulation-based training, outcomes monitoring, and reimbursement support-have become key differentiators that influence purchasing decisions. For incumbent firms, defending market position requires continuous innovation and operational excellence, whereas new entrants must demonstrate clear clinical benefit and pathway integration to overcome entrenched procurement processes.

Actionable strategic priorities for manufacturers and health system leaders to secure clinical adoption, strengthen supply chains, and align reimbursement pathways

Industry leaders should pursue a three-pronged approach that balances portfolio focus, operational resilience, and stakeholder engagement. First, prioritize investments in modular platforms and adjunctive services that demonstrably reduce procedure time, complications, and downstream resource utilization. Such solutions should be supported by pragmatic clinical studies and real-world outcomes initiatives that resonate with both clinicians and procurement teams. Second, mitigate supply chain risk by diversifying suppliers, qualifying regional manufacturing options, and negotiating flexible contracts that share cost volatility with trading partners. This will preserve margin integrity while enabling responsive supply continuity during policy or logistic disruptions.

Third, embed commercialization with education and evidence generation; develop scalable training programs and digital tools that accelerate clinician adoption and capture post-market performance data. Complement these initiatives with targeted engagement of payers and hospital value committees to align reimbursement and purchasing incentives. Finally, consider strategic partnerships or licensing arrangements that accelerate market entry for niche innovations while conserving capital. By executing concurrently on product differentiation, supply chain resilience, and stakeholder alignment, industry leaders can translate innovation into sustainable market access and clinical impact.

Transparent methodological framework combining primary clinician and procurement interviews with rigorous secondary evidence synthesis and scenario-based validation

This research synthesized primary stakeholder interviews, secondary literature review, and cross-validation of clinical and commercial data to ensure methodological rigor and transparency. Primary inputs included structured discussions with interventional clinicians, hospital procurement leaders, and supply chain executives to surface practical constraints, adoption barriers, and clinical preferences. Secondary research encompassed peer-reviewed clinical studies, regulatory filings, and public procurement documentation to verify device and therapy characteristics and to triangulate reported trends.

Analytical methods blended qualitative thematic analysis with quantitative cross-tabulation of adoption drivers and outcome correlates. Evidence hierarchies were applied to weigh randomized clinical trial data alongside registry and real-world evidence, ensuring policy-relevant conclusions. Sensitivity checks and scenario testing were conducted to assess the robustness of insights against plausible variations in reimbursement and supply chain conditions. Throughout, emphasis was placed on traceable data provenance and reproducible logic so that findings can inform both tactical commercial decisions and longer-term R&D prioritization.

Synthesis of strategic implications and the critical interplay between clinical evidence, operational execution, and supply chain agility shaping future success

The vascular injury treatment landscape is at an inflection point where technological maturity, policy shifts, and evolving care delivery models converge to create opportunity and complexity. Device and pharmacologic innovators who align product capabilities with demonstrable clinical and operational benefits will secure preferential access to procurement pathways. Changes in trade and supply dynamics have heightened the strategic importance of manufacturing flexibility and contractual innovation, while regional heterogeneity in regulation and reimbursement mandates localized approaches to market entry.

Ultimately, success will depend on the ability to integrate product innovation with education, evidence generation, and supply chain resilience. Stakeholders that invest in outcome-focused value propositions and scalable implementation support will be best positioned to influence care pathways and capture long-term value. The path forward favors collaborators that can bridge clinical excellence with practical, system-level solutions, thereby improving patient outcomes while delivering sustainable commercial returns.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expanding applications of drug eluting balloons for complex peripheral vascular injury management
  • 5.2. Surge in endovascular robotic assistance systems improving precision in trauma induced injuries
  • 5.3. Development of multifunctional hemostatic dressings integrating nanoparticles for rapid bleeding control
  • 5.4. Adoption of AI driven predictive analytics for optimizing treatment pathways in vascular trauma patients
  • 5.5. Growth in minimally invasive percutaneous mechanical thrombectomy devices for arterial injury repair
  • 5.6. Increasing collaboration between biotech firms and academic centers for regenerative vascular therapies
  • 5.7. Rise of 3D printed customizable vascular grafts enhancing compatibility in complex injuries
  • 5.8. Enhanced focus on hemodynamic monitoring technologies to improve outcomes in vascular trauma

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Injury Treatment Market, by Product

  • 8.1. Catheters
    • 8.1.1. Aspiration Catheters
    • 8.1.2. Balloon Catheters
    • 8.1.3. Delivery Catheters
  • 8.2. Embolic Protection Devices
    • 8.2.1. Distal Filters
    • 8.2.2. Proximal Occlusion Devices
  • 8.3. Stents
    • 8.3.1. Bare Metal Stents
    • 8.3.2. Covered Stents
    • 8.3.3. Drug Eluting Stents
  • 8.4. Thrombolytic Drugs
    • 8.4.1. Streptokinase
    • 8.4.2. Tissue Plasminogen Activator
    • 8.4.3. Urokinase
  • 8.5. Vascular Grafts
    • 8.5.1. Biological Grafts
    • 8.5.2. Synthetic Grafts

9. Vascular Injury Treatment Market, by Treatment Modalities

  • 9.1. Endovascular Repair
    • 9.1.1. Aortic Stenting
    • 9.1.2. Carotid Stenting
    • 9.1.3. Peripheral Stenting
  • 9.2. Open Surgery
  • 9.3. Pharmacotherapy
    • 9.3.1. Anticoagulants
    • 9.3.2. Antiplatelet Drugs
    • 9.3.3. Thrombolytics

10. Vascular Injury Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Vascular Injury Treatment Market, by Injury Type

  • 11.1. Arterial Injury
  • 11.2. Capillary Injury
  • 11.3. Microvascular Injury
  • 11.4. Venous Injury

12. Vascular Injury Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vascular Injury Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vascular Injury Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Abbott Laboratories
    • 15.3.3. Boston Scientific Corporation
    • 15.3.4. Johnson & Johnson
    • 15.3.5. W. L. Gore & Associates, Inc.
    • 15.3.6. Terumo Corporation
    • 15.3.7. B. Braun Melsungen AG
    • 15.3.8. Becton, Dickinson and Company
    • 15.3.9. Teleflex Incorporated
    • 15.3.10. Edwards Lifesciences Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. VASCULAR INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. VASCULAR INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VASCULAR INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ASPIRATION CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ASPIRATION CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ASPIRATION CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DELIVERY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DELIVERY CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DELIVERY CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DELIVERY CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DELIVERY CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DELIVERY CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DISTAL FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DISTAL FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DISTAL FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DISTAL FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DISTAL FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DISTAL FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PROXIMAL OCCLUSION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COVERED STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COVERED STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COVERED STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COVERED STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COVERED STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY COVERED STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STREPTOKINASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STREPTOKINASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STREPTOKINASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STREPTOKINASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STREPTOKINASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY STREPTOKINASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TISSUE PLASMINOGEN ACTIVATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY UROKINASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY UROKINASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY UROKINASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY UROKINASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY UROKINASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY UROKINASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BIOLOGICAL GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BIOLOGICAL GRAFTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BIOLOGICAL GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BIOLOGICAL GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BIOLOGICAL GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY BIOLOGICAL GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SYNTHETIC GRAFTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SYNTHETIC GRAFTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SYNTHETIC GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SYNTHETIC GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SYNTHETIC GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SYNTHETIC GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AORTIC STENTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AORTIC STENTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AORTIC STENTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AORTIC STENTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AORTIC STENTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AORTIC STENTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAROTID STENTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAROTID STENTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAROTID STENTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAROTID STENTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAROTID STENTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAROTID STENTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PERIPHERAL STENTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PERIPHERAL STENTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PERIPHERAL STENTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PERIPHERAL STENTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PERIPHERAL STENTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PERIPHERAL STENTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY OPEN SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTICOAGULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ANTIPLATELET DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ARTERIAL INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ARTERIAL INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ARTERIAL INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ARTERIAL INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ARTERIAL INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY ARTERIAL INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAPILLARY INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAPILLARY INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAPILLARY INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAPILLARY INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAPILLARY INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY CAPILLARY INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY MICROVASCULAR INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY MICROVASCULAR INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY MICROVASCULAR INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY MICROVASCULAR INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY MICROVASCULAR INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY MICROVASCULAR INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VENOUS INJURY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VENOUS INJURY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VENOUS INJURY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VENOUS INJURY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VENOUS INJURY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY VENOUS INJURY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VASCULAR INJURY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY INJURY TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY THROMBOLYTIC DRUGS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY VASCULAR GRAFTS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY ENDOVASCULAR REPAIR, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA VASCULAR INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA V